Uniqure (QURE) Downgraded by BidaskClub to Hold

Uniqure (NASDAQ:QURE) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday.

Several other equities analysts have also recently weighed in on QURE. B. Riley started coverage on shares of Uniqure in a research report on Wednesday, June 27th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright set a $42.00 price objective on shares of Uniqure and gave the stock a “buy” rating in a research report on Friday, June 29th. Zacks Investment Research raised shares of Uniqure from a “hold” rating to a “buy” rating and set a $44.00 target price for the company in a research note on Wednesday, July 4th. Cantor Fitzgerald initiated coverage on shares of Uniqure in a research note on Thursday, July 26th. They set an “overweight” rating and a $58.00 target price for the company. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $45.56.

NASDAQ QURE opened at $29.14 on Tuesday. Uniqure has a twelve month low of $9.47 and a twelve month high of $43.23. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.36 and a current ratio of 8.36. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -9.91 and a beta of 0.27.

Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.04. Uniqure had a negative net margin of 677.98% and a negative return on equity of 72.12%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.37 million. As a group, equities analysts expect that Uniqure will post -2.44 earnings per share for the current year.

Several large investors have recently modified their holdings of the business. Quantbot Technologies LP lifted its stake in shares of Uniqure by 3,972.6% in the 1st quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock valued at $129,000 after purchasing an additional 5,363 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Uniqure by 276.5% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 4,700 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new stake in shares of Uniqure in the 1st quarter valued at $177,000. Gagnon Securities LLC acquired a new stake in shares of Uniqure in the 2nd quarter valued at $209,000. Finally, Jane Street Group LLC acquired a new stake in shares of Uniqure in the 1st quarter valued at $224,000. 59.32% of the stock is owned by institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Further Reading: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply